Method of treating lung cancer

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology and concerns treating lung cancer. That is ensured by 6 therapeutic sessions every 21 day according to the scheme: the patient is exposed to hyperbaric oxygenation at pressure 1.3 atm, 30 min daily for 5 days; and then chemotherapeutic preparations are administered as follows: on the 6th day, kemoplat dissolved in 0.9% sodium chloride is administered in a dose of 75 mg/m2 of the patient's body; on the 6th, 8th and 10th days, phytoside 120 mg/m2 of the patient's body dissolved in 0.9% sodium chloride is administered.

EFFECT: dose schedule of the chemopreparations in a combination with the hyperbaric oxygenation provides reducing such side effects of the chemotherapy as leukopenia and anaemia that in turn enables the following sessions of chemotherapy in the prescribed time and thereby increasing the clinical effectiveness in lung cancer.

1 ex

 

The invention relates to the field of medicine and more specifically to methods for treating cancer lung cancer patients.

There is a method of treatment of cancer by intravenous chemotherapeutic drugs (1).

The disadvantage of this method is the occurrence of toxic side reactions and, as a consequence, the postponement of the next course of chemotherapy, which negatively affects the efficiency of the treatment.

Side effects of chemotherapy is often limiting, i.e. not to allow the continued use of drug treatment. For most anticancer agents toxic effect corresponding to the third degree of toxicity, and more, is an indication for termination of chemotherapy and requires intensive symptomatic treatment. The possibility of resumption of chemotherapy depends on the completeness and rate of elimination of adverse reactions and complications that directly affects the efficiency of the treatment.

Malignant neoplasms lead to the development of tissue oxygen deficiency (hypoxia) or directly associated with acute or chronic hypoxia. Hypoxia is a decrease in oxygen tension in body tissues (pO2) due to violation of its delivery or disposal. The severity of HYPOXI which often determines the outcome of the disease. Particularly sensitive to hypoxia of the brain and heart.

In patients with malignant tumors hypoxia can occur for various reasons is a violation of the patency of the vessels supplying the organ (atherosclerosis, inflammation, swelling, and other), and lowering the amount of hemoglobin, and many other reasons. Originating from primary or secondary, hypoxia leads to a cascade of reactions that exacerbate the underlying disease course that is exacerbating the lack of oxygen. Hypoxia ultimately leads to energy shortages cells - a universal outcome of almost all forms of its pathology. For treatment of this condition has developed different methods of oxygen therapy (oxygen therapy). However, at normal atmospheric pressure even breathing pure oxygen is often not able to eliminate the oxygen deficiency at the level of cells, organs and tissues.

Hyperbaric oxygenation (HBO) increases the oxygen capacity of the liquid media of the organism by increasing the dilution of oxygen and is able to compensate for the metabolic needs of the body of oxygen in any form of hypoxia.

The aim of the invention is to improve the efficacy and reduce toxicity of the treatment in patients with lung cancer.

This goal is achieved by the fact that they have 6 courses l is the treatment at intervals of 21 days for the scheme: the patient is subjected to HBO at a pressure of 1.3 ATM. 30 minutes daily for 5 days, and then injected chemotherapy drugs: on the 6th day enter camoplast at a dose of 75 mg/m2the body of the patient, diluted in 0.9% solution of sodium chloride, 6-th, 8-th, 10-th day enter fitted at a dose of 120 mg/m2the body of the patient, diluted in 0.9% sodium chloride solution.

Patients who have shown chemotherapy, are 6 courses of chemotherapy, following one after the other, and between the first introduction of one course and the first introduction of the next course should be taken exactly 21 days. Each course includes HBO at a pressure of 1.3 ATM. 30 minutes daily for 5 days, on day 6, the patient is given camoplast at a dose of 75 mg/m2the body of the patient, diluted in 0.9% solution of sodium chloride, 6-th, 8-th, 10-th day the patient is also administered intravenously drip fitted at a dose of 120 mg/m of a patient's body, diluted in 0.9% sodium chloride solution.

Clinical example. Patient B., 51 years with a diagnosis of Cancer of the upper lobe of the right lung, CT3N1M1. Cllr. 2." was held chemotherapeutic treatment, including 6 courses according to the following scheme. Each course includes HBO at a pressure of 1.3 ATM. 30 minutes daily for 5 days, on day 6, the patient is given camoplast 75 mg/m2the body of the patient, diluted in 0.9% solution of sodium chloride, 6-th, 8-th, 10-th day the patient also enter the t intravenous drip fitted at a dose of 120 mg/m 2the body of the patient, diluted in 0.9% sodium chloride solution. 1-day one of the course before the 1st day of the next course would be exactly 21 days. The result was achieved stable remission at 9 months.

The positive effect from the use of the invention is expressed in reducing the severity of nausea and vomiting in patients in reducing the incidence and severity of leukopenia (reduction in the number of leukocytes in the blood) and anemia (decreased number of red blood cells), in the conduct of subsequent chemotherapy courses within the established term. What is crucial in the treatment of chemotherapy drugs.

The invention is possible and appropriate to use in Oncology for the treatment of lung cancer.

Sources of information

1. Guidelines for chemotherapy of neoplastic diseases / Ed. by N.I. Perevozchikova. - 3rd edition, supplementary and Rev. Practical medicine. - Moscow, 2011. - P.143.

2. Queen, I.A. the Prevention of nausea and vomiting when conducting cytostatic therapy in adults. / IA Queen, Kopp MV. - Farmateka. No. 6, 2010, P.30-34.

3. Petrovsky, BV Basis of hyperbaric oxygenation / BV Petrovsky, S. Epuni. - M, Medicine, 1976, 346 S.

4. Treatment of high pressure oxygen / Lane. from English. I.P. Berezina, GI Gayev. Under. editor Professor L.L. Chic, Kida. technology. Sciences T.A. Sultanov. - M, Medicine 1968. - 288 S.

The method of treatment of cancer lung cancer patients by intravenous chemotherapy drugs, characterized in that they have 6 treatments with intervals of 21 days for the scheme: the patient is subjected to HBO at a pressure of 1.3 ATM. 30 min daily for 5 days, and then injected chemotherapy drugs: on the 6th day enter camoplast at a dose of 75 mg/m2the body of the patient, diluted in 0.9%solution of sodium chloride, 6-th, 8 th, 10 th days enter fitted at a dose of 120 mg/m2the body of the patient, diluted in 0.9%sodium chloride solution.



 

Same patents:

Novel antibodies // 2490277

FIELD: chemistry.

SUBSTANCE: present invention relates to immunology. Disclosed is an anti-α5β1 antibody, which is described through amino acid sequences of six hypervariable regions and an antigen-binding moiety thereof. Described are conjugates of the disclosed antibodies with a medicinal agent or a label, a pharmaceutical composition, use of the disclosed antibodies to prepare a medicinal agent, methods and an industrial product for inhibiting angiogenesis and/or vascular permeability in a subject, and for treating cancer, an ophthalmic disease and an autoimmune disease in a subject. The invention describes an isolated nucleic acid, an expression vector, a cell and a method of producing an antibody or an antigen-binding moiety thereof, as well as a method of detecting α5β1 protein in a sample.

EFFECT: present invention can find further use in therapy and diagnosis of α5β1-mediated diseases.

52 cl, 11 dwg, 6 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and specifically to novel morpholinopurine derivatives of general formula

,

or a pharmaceutically acceptable salt thereof, where R1 and R2, each independent of each other, denote a C1-C6 alkyl group or a hydrogen atom, R3a and R3b, each independent of each other, denote a C1-C6 alkyl group which can contain three substitutes selected from a group A, or a hydrogen atom, R4 denotes a C1-C6 alkyl group or a hydrogen atom, Ra denotes a group of formula -Y-R , where Y denotes a single bond or a C1-C6 alkylene group, R5 is a C1-C6 alkyl group which can contain one, two or three substitutes selected from group A, a tetrahydrofuranyl group, a pyrrolidinyl group which contains one substitute selected from a group D, and Rb and Rc, each independent of each other, denote a C1-C6 alkyl group which contains one substitute selected from a group E, or a hydrogen atom, or Rb and Rc, together with a nitrogen atom to which they are bonded, for a 5-7-member alicyclic nitrogen-containing heterocyclic group, which is pierazine, morpholine, pyrrolidine, piperidine, homopiperazine, which can contain one, two or three substitutes selected from group E; group A: halogen atom, hydroxy group, C3-C8 cycloalkyl group and oxy group; group D: C1-C6 alkylsulphonyl group; and group E: hydroxy group, formyl group, C1-C6 alkyl group, which can contain one substitute selected from said group A, diC1-C6 alkylamino group, C1-C6 alkylsulphonylamino group, C1-C6alkylsulphonyl C1-C6 alkylamino group, C1-C6 alkylsulphonylamino C1-C6alkyl group, C1-C6alkylcarbonyl group, which can contain one substitute selected from said group A, C1-C6 alkylsulphonyl group, C1-C6 alkylamino C1-C6 alkylcarbonyl group, diC1-C6 alkylamino C1-C6alkylcarbonyl group, which can contain one substitute selected from said group A, diC1-C6 alkylaminocarbonyl group, phenylsulphonyl group and hateroaryl C1-C6 alkylcarbonyl group, where the heteroaryl is imidazolyl. The invention also relates to a pharmaceutical composition, an inhibitor of phosphatidylinositol-3-kinase (PI3K), an inhibitor of mammalian target of rapamycin (mTOR) based on the compound of formula (1a), a method of treating cancer and use of the compound of formula (1a).

EFFECT: obtaining novel morpholinopurine derivatives, having useful biological properties.

42 cl, 19 tbl, 138 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a 2H-chromen compound or a derivative thereof having action of a S1P1 agonist. The above may be used for preventing and/or treating a disease caused by undesired lymphocyte filtration, or a disease caused by abnormal cell proliferation or accumulation.

EFFECT: preparing the compounds for preventing and/or treating the disease caused by undesired lymphocyte filtration, or the disease caused by abnormal cell proliferation or accumulation.

8 cl, 131 tbl, 156 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of formula

,

using them as tubulin polymerisation inhibitors and PARP inhibitors, and also as an ingredient of pharmaceutical compositions containing the above compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and Y have the values specified in the patent claim.

EFFECT: preparing intermediate compounds for preparing the compounds of formula (I) and a method for preparing the intermediate compounds.

16 cl, 3 tbl, 40 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an acid addition salt of a compound of formula (1), formed by L-lactic acid. The compound (1) can be used as a Hsp90 inhibitor. Described are methods of producing a compound of formula (1), intermediate compounds used to produce a compound of formula (1) and methods of producing the intermediate compounds.

EFFECT: obtaining an acid addition salt of a compound of formula (1), formed by L-lactic acid.

10 cl, 22 dwg, 4 dwg, 22 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to oncology and radiology. The method involves the local radiation therapy sessions in a dynamic dose fractionation mode. Additionally, 3 times a week the local radiation therapy session is immediately followed by subtotal irradiation of the upper body from a suprasternal notch to a diaphragm. Thereafter, 21-28 days after the local radiation therapy completed, min. 4 cycles of the chemotherapy with each cycle combined with subtotal irradiation of the upper body from the suprasternal notch to the diaphragm 3 times a week.

EFFECT: method enables reducing a risk of developing a local recurrence of the tumour and metastases to 10,7% as compared to the previously known methods (15%), as well as a severity of complications with achieving the complete objective response to the treatment in 35,7% of the patients, and the partial response - in 46,42%.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and may be used for the purpose of the integrated treatment of the patients with II-IV breast cancer. That is ensured by administering cytostatic preparations after the one-stage chemotherapy, including: cyclophosphan (500 mg/m2) and doxorubicin (50 mg/m2) (the schedule AC) or cyclophosphan (500 mg/m2), doxorubicin (50 mg/m2) and fluorouracil (500 mg/m2) (the schedule FAC) intravenously. Besides, the preparation Panagen in the form of gastroenteric-coated tablets 30 mg/day is regularly divided over an active period of day that makes one tablet of the preparation Panagen for six times every two hours; the administration starts on the third day following the chemotherapy. The length of the administration of the preparation Panagen is 17 days and continued until the chemotherapeutic courses according to the above schedules completed.

EFFECT: method enables the higher clinical effectiveness in breast cancer that ensures preserving and stimulating granulocyte-macrophage and lymphocyte hematopoietic lineages that makes compensation for the negative effect of leukoreducing effect of the cytostatic preparations.

1 cl, 40 dwg

FIELD: biotechnologies.

SUBSTANCE: invention relates to compounds of general formula I, having cytostatic or cytotoxic activity, its pharmaceutically acceptable salts, tautomers or stereoisomers, a pharmaceutical composition on their basis. Compounds may be used for treatment of cancerous diseases. In the general formula I

Y is selected from the group comprising -CHRay- and -CHRay-CRby-CRcy-; each Ray, Rby and Rcy are independently selected from hydrogen and non-substitute C1-C12-alkyl; each R1, R2, R3, R4 and R5 are independently selected from hydrogen and non-substitute C1-C12-alkyl; R6 is selected from NR8R9 and OR10; A means , W means NR7; R7 means hydrogen; R8 means hydrogen; R10 means non-substitute C2-C12-alkenyl; each dotted line means unnecessary additional link, but when there is a triple link between atoms of carbon, to which R1 and R2 are attached, then R1 and R2 are absent, and when there is a triple link between carbon atoms, to which R3 and R4 are attached, then R3 and R4 are absent; R9 is selected from substitute C2-C12-alkenyl and substitute C4-C|2-alkenylyl, where substitutes are selected from the group, consisting of: halogen, OR', OCONHR' and OH, protected with a simple silyl ether; where R' means hydrogen; provided that whenever Y means -CHRay-CRby=CRcy- and there is a single or double link between atoms of carbon, to which R3 and R4 are attached, then R9 means substitute C4-C12-alkenylyl; and each R16, R17 and R18 are independently selected from hydrogen and ORa; each Ra is selected from hydrogen or non-substitute C1-C12-alkyl.

EFFECT: higher efficiency of compound application.

FIELD: biotechnologies.

SUBSTANCE: invention relates to new compounds of the formula I:

or its pharmaceutically acceptable salts, where values R1, R2, R3, R3', R4, R4', X2, X1, X3, X4, X5, R6, R7, R5', R6', R7', R14', R8, R9, R10, R11a, b, c are specified in the clause 1 of the formula.

EFFECT: compounds demonstrate antitumoral activity and may be used to produce a pharmaceutical composition for tumor treatment in a mammal.

14 cl, 18 dwg, 1 tbl, 52 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and may be used for the purpose of the integrated treatment of the patients with oncological diseases. For this purpose, a drug preparation of cytostatic group and a drug preparation of fragmented double-stranded DNA with fragments having a biologically active size and making a complete genome of a physiologically and genetically healthy donor in the form of tablets is administered into the patient's body. A tablet containing 5 mg of the active ingredient is used according to the scheme in 30 min and 2, 3 and 5 days after the administration of cyclophosphan in the amount of one tablet in the first 30 minutes after the administration of cyclophosphan. Further on these days, one tablet is taken every 2-3 hours a day while awake, but no more than 30 mg of the active ingredient a day.

EFFECT: use of the given method enables achieving an increase of mature dendritic cell count in the body that allows achieving the maximum development of the retrogressive effect on the tumour.

1 ex, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is liquid composition of elsamitrucin for treatment of tumorour diseases or conditions, including: a) at least one stable salt of elsamitrucin, which represents product of free elsamitrucin base and organic acid and can exist as stable solid substance and does not include pseudo-salts or salts, obtained in situ, which exist only in solution, and b) pharmaceutically acceptable carrier, and claimed liquid composition does not contain antioxidants or methanol, ethanol, chloroform, n-butanol or t-butanol as admixtures, and claimed stable salt of elsamitrucin preserves at least 90% of its anti-tumor activity within 18 months in liquid form at appropriate storage temperature.

EFFECT: it is shown, that compositions, namely disclosed in claimed invention water solutions of true elsamitrucin salts, can be preserved and introduced without reduction before application.

16 cl, 7 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatovenerology, and may be used for the preventive differentiated treatment of the individuals being in contact with the patients suffering the infectious stage of syphilis. That is ensured by the single oral administration of azithromycin (Sumamed) 1.0 g in the period of incubation up to 14 days, 1.5 g in the period of incubation of 15-30 days and 2.0 g in the period of incubation of 31-60 days.

EFFECT: method consists in the effective preventive differentiated therapy of the individuals being in contact with the patients suffering the infectious stage of syphilis and has minimal side effects due to the optimal dose in accordance with the period of incubation.

4 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and aims at the preventive therapy of children who had close domestic contact with the patients suffering the infectious stage of syphilis. The method involves administering a single oral dose of a flavoured suspension of azithromycin (Sumamed) 10 mg per kg of children's body weight for 5 days.

EFFECT: use of the declared method prevents the development of the infection in children and reduces the length of the preventive therapy by two times.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutical industry and represents a pharmaceutical composition for topical administration comprising the active ingredients in the form of 0.001-5.0 wt % of deoxyribonuclease (DNA-ase) and 0.001-5.0 wt % of glycyrrhizinic acid or a salt thereof: ammonium or dipotassium or trisodium glycyrrhizinate, as carriers: β-cyclodextrins 0.001-5.0 wt % and pharmaceutically acceptable carriers or excipients, which may be used in medicine for treating and preventing viral infections caused by DNA-containing viruses, such as herpes simplex, herpes zoster, human papilloma.

EFFECT: invention provides improved stability, potentiated complex antiviral effect.

2 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science, and aims at treating respiratory diseases in young farm animals. The complex preparation tylocolin is administered to the animals once a day for 3-5 days intramuscularly. A dose is 0.05 ml/kg of body weight in calves, and 0.075 ml/kg of body weight in piglets.

EFFECT: use of the method enables higher clinical effectiveness in the respiratory diseases of young farm animals.

5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a formulation for delivery of amphotericin B and other drugs, wherein the formulation contains an active ingredient, one or more esters of glycerol and fatty acids and one or more esters of fatty acids containing polyoxyethylene oxide, wherein the ratio of esters of glycerol and fatty acids and esters of fatty acids containing polyoxyethylene oxide makes from approximately 20:80 to approximately 80:20 vol/vol.

EFFECT: formulation is applicable for preparing the drug with improved bioavailability for infectious diseases.

13 cl, 21 dwg, 8 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutical compositions for treating or preventing C. difficile infection in an individual. The composition is presented in the form of a solid dosage form and contains a therapeutically effective amount in tiacumicine, a stabilising amount of one or more antioxidants, such as butylated hydroxytoluene, and optionally one or more pharmaceutically acceptable excipients. The invention also refers to a method of treating C. difficile associated diarrhea using the given composition.

EFFECT: compositions of the invention have a high stability and a long shelf life.

14 cl, 5 dwg, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a composition and a combination for treating panniculopathy and problems associated with venous insufficiency of the lower limbs. The composition for treating panniculopathy and problems associated with venous insufficiency of the lower limbs, containing esculoside and at least one compound selected from icarine or its derivatives, or extracts containing it (them), Gingko biloba dimer flavones in a free form or complexed with phospholipids, amentoflavone and at least one compound selected from escin, escin beta sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, or Centella asiatica extract in a free form or complexed with phospholipids. The use of the combination on the basis of the mentioned ingredients for preparing the composition for treating panniculopathy and problems associated with venous insufficiency of the lower limbs.

EFFECT: above-described composition and combination are effective in reducing panniculopathy and problems associated with venous insufficiency of the lower limbs.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. A dosage form for treating mycotic infections contains nanosomes of cholesterol-containing amphotericin B of the diameter within the range of 20-200 nm in physiologic saline, the ratio of lipid to amphotericin B ranges from 45:1 to 45:15. Amphotericin B is exposed to ultrasound to destruct at the final stage to transform the particles into smaller and less lamellar nanosomes.

EFFECT: invention provides lower nephrotoxicity and effective antimycotic activity.

3 cl, 11 tbl, 3 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The method of producing 1--D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) involves reaction of excess guanosine with 1,2,4-triazole-3-carboxamide in a potassium phosphate buffer in the presence of sodium arsenate and purine nucleoside phosphorylase.

EFFECT: invention enables 100% conversion of guanosine to guanine and simplifies the process of separating the end product from the reaction mixture.

3 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to oncology and radiology. The method involves the local radiation therapy sessions in a dynamic dose fractionation mode. Additionally, 3 times a week the local radiation therapy session is immediately followed by subtotal irradiation of the upper body from a suprasternal notch to a diaphragm. Thereafter, 21-28 days after the local radiation therapy completed, min. 4 cycles of the chemotherapy with each cycle combined with subtotal irradiation of the upper body from the suprasternal notch to the diaphragm 3 times a week.

EFFECT: method enables reducing a risk of developing a local recurrence of the tumour and metastases to 10,7% as compared to the previously known methods (15%), as well as a severity of complications with achieving the complete objective response to the treatment in 35,7% of the patients, and the partial response - in 46,42%.

1 ex

Up!